Cited by 143Neurotransmitter Receptor Influence on BehaviorNeural and Behavioral Psychology StudiesSchizophrenia research and treatment

Dissociable control of impulsivity in rats by dopamine D2/3 receptors in the core and shell subregions of the nucleus accumbens

Open access
Besson, Morgane, Belin, David, McNamara, Ruth, Theobald, David EH, Castel, Aude, Beckett, Victoria L, Crittenden, Ben M, Newman, Amy H +3 more·2010·Neuropsychopharmacology

Abstract

Previous research has identified the nucleus accumbens (NAcb) as an important brain region underlying inter-individual variation in impulsive behavior. Such variation has been linked to decreased dopamine (DA) D2/3 receptor availability in the ventral striatum of rats exhibiting spontaneously high levels of impulsivity on a 5-choice serial reaction time (5-CSRT) test of sustained visual attention. This study investigated the involvement of DA D2/3 receptors in the NAcb core (NAcbC) and the NAcb shell (NAcbS) in impulsivity. We investigated the effects of a DA D2/3 receptor antagonist (nafadotride) and a DA D2/3 partial agonist (aripiprazole) infused directly into either the NAcbC or NAcbS of rats selected for high (HI) and low (LI) impulsivity on the 5-CSRT task. Nafadotride increased significantly the level of impulsivity when infused into the NAcbS, but decreased impulsivity when infused into the NAcbC of HI rats. By contrast, intra-NAcb microinfusions of aripiprazole did not affect impulsivity. Systemic administration of nafadotride had no effect on impulsive behavior but increased the number of omissions and correct response latencies, whereas systemic injections of aripiprazole decreased impulsive and perseverative behavior, and increased the number of omissions and correct response latencies. These findings indicate an opponent modulation of impulsive behavior by DA D2/3 receptors in the NAcbS and NAcbC. Such divergent roles may have relevance for the etiology and treatment of clinical disorders of behavioral control, including attention-deficit hyperactivity disorder and drug addiction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2009.162

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Besson, M., Belin, D., McNamara, R., Theobald, D. E., Castel, A., Beckett, V. L., Crittenden, B. M., Newman, A. H., Everitt, B. J., Robbins, T. W., & Dalley, J. W.
Affiliations
  • University of Cambridge (GB)
  • National Institutes of Health (US)
Corresponding author
Dalley, Jeffrey W
Venue
Neuropsychopharmacology
Published
2009-10-21
Volume
35
Issue
2
Pages
560-569
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2054111217
Cited by
143
References
53
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 5 · 2018: 10 · 2017: 11 · 2016: 9 · 2015: 13 · 2014: 12 · 2013: 25 · 2012: 6
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust (076274)
  • Medical Research Council
  • National Institute on Drug Abuse
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
impulsivity, dopamine D2/D3 receptors, nucleus accumbens, nucleus accumbens core, nucleus accumbens shell, aripiprazole, 5-choice serial reaction time task, sustained visual attention, perseveration, interindividual variability, attention deficit hyperactivity disorder, drug addiction
MeSH terms
Aripiprazole, Analysis of Variance, Animals, Attention, Choice Behavior, Dose-Response Relationship, Drug, Drug Administration Routes, Impulsive Behavior, Male, Naphthalenes, Neuropsychological Tests, Nucleus Accumbens, Piperazines, Pyrrolidines, Reaction Time, Quinolones, Receptors, Dopamine D2, Dopamine Antagonists, Receptors, Dopamine D3, Rats, Dopamine D2 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review